Leqvio (inclisiran) / Alnylam, Novartis  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Leqvio (inclisiran) / Novartis
NCT02314442: A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Checkmark Interim data from study in healthy volunteers with elevated LDL-C at AHA 2015
Nov 2015 - Nov 2015: Interim data from study in healthy volunteers with elevated LDL-C at AHA 2015
Checkmark For hypercholesterolemia at ESC
Aug 2015 - Aug 2015: For hypercholesterolemia at ESC
Completed
1
70
Europe
ALN-PCSSC, Sterile Normal Saline (0.9% NaCl)
Alnylam Pharmaceuticals, The Medicines Company
Hypercholesterolemia
05/15
11/15
ORION-7, NCT03159416: A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function

Completed
1
31
RoW
Inclisiran, ALN-PCSSC
The Medicines Company
Renal Impairment
03/18
03/18
ORION-14, NCT04774003: Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C

Completed
1
40
RoW
100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran), KJX839, Placebo, 300 mg inclisiran sodium (equivalent to 284 mg inclisiran)
Novartis Pharmaceuticals
Hyperlipidemia
10/21
10/21

Download Options